See all locations for this study
Phase 2Recruiting

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Sponsored by Fox Chase Cancer Center

About this study

This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.

Enrolling at this location

Fox Chase Cancer Center

Philadelphia, Pennsylvania

I'm interested

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.